Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adjuvant aspirin and Cyclooxygenase-2 inhibitors in resected, PIK3CA-mutated colorectal cancer: A systematic review and meta-analysis of randomized controlled trials.

Critical reviews in oncology/hematology - 1 Apr 2026

Blanchard-Cavagis Ellen R, Abrahão Reis Pedro C, Visani Filipe Luis Vasconcelos, Carneiro Brito Heloísa, Diniz Isabela C, Dabbous de Liz Caio

Abstract excerpt

BACKGROUND: Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are widely available and inexpensive agents with proposed antitumor activity, particularly in tumors harboring PIK3CA mutations. This meta-analysis of randomized controlled trials (RCTs) evaluated whether adjuvant NSAID therapy improves outcomes in patients with resected PIK3CA-mutated colorectal cancer (CRC). METHODS: PubMed, Embase, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Inflammatory Agents, Non-Steroidal
Share to Aspirin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Class I Phosphatidylinositol 3-Kinases

Share to Colorectal Neoplasms

Share to Cyclooxygenase 2 Inhibitors

Share to Mutation

Share to Randomized Controlled Trials as Topic

Source

Identifiers

PMID: 41621633
DOI: 10.1016/j.critrevonc.2026.105167

Genes

PIK3CA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adjuvant aspirin and Cyclooxygenase-2 inhibitors in resected, PIK3CA-mutated colorectal cancer: A systematic review and meta-analysis of randomized controlled trials.PMID 41621633Read ↗

Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance).Semantic proximity Read ↗

Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.Semantic proximity Read ↗

Adjuvant aspirin for colorectal cancer with PIK3CA-mutated and COX-2 overexpressed tumours: the ASCOLT translational research study and meta-analysis.Semantic proximity Read ↗

PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies.Semantic proximity Read ↗

Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer.Semantic proximity Read ↗

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.Semantic proximity Read ↗

Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation.Semantic proximity Read ↗

Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population-Based Cohort StudySemantic proximity Read ↗

Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis.Semantic proximity Read ↗

The Association Between Colorectal Cancer and Pharmaceuticals with Emphasis on Low-Dose Aspirin and AnticoagulantsSemantic proximity Read ↗

Potential biomarker for aspirin use in colorectal cancer therapy.Semantic proximity Read ↗

Aspirin and Cancer: An Updated MinireviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.